The lungs and airways rely on a network of immune structures to filter pathogens, respond to inflammation, and flag abnormal cells before they spread. Among these structures, hilar lymph nodes play a particularly important role, sitting at the root of each lung where the major airways and blood vessels converge. Understanding their function, the conditions that cause them to enlarge, and how physicians diagnose and treat those conditions can help patients make sense of findings on a chest imaging report.
Key Takeaways
- Hilar lymph nodes are located at the lung roots, where the bronchi and pulmonary vessels enter each lung.
- Enlargement of these nodes — called hilar lymphadenopathy — is most commonly caused by infection, sarcoidosis, or malignancy.
- Bilateral hilar lymphadenopathy, in which both sides are affected simultaneously, is a hallmark finding in sarcoidosis.
- A chest X-ray is often the first imaging tool used to detect enlarged hilar lymph nodes, with CT and biopsy confirming the diagnosis.
- Treatment depends entirely on the underlying cause and can range from antibiotics to chemotherapy or immunosuppressive therapy.
What Are Hilar Lymph Nodes and Where Are They Located
Hilar lymph nodes are small, bean-shaped immune glands situated at the hilum of each lung — the central region where the bronchi, pulmonary arteries, pulmonary veins, and lymphatic vessels enter or exit the lung tissue. Each hilum functions as a gateway, and the lymph nodes positioned there act as surveillance checkpoints, filtering lymphatic fluid that drains from the bronchi, lung parenchyma, and surrounding pleura. Because of their central location, they are among the first sites to respond when infection, inflammation, or abnormal cell growth arises in the chest.
The lymphatic system as a whole contains approximately 600 to 700 lymph nodes throughout the body, though only those in strategically significant regions tend to become clinically relevant on imaging. The hilar group is particularly important because it communicates directly with mediastinal lymph nodes — nodes situated in the central chest cavity between the lungs — creating a pathway through which disease can travel from the lungs toward the heart, esophagus, and great vessels. Radiologists and pulmonologists evaluate hilar node size and symmetry routinely when reviewing chest imaging, as changes in these nodes often serve as early indicators of systemic disease.
Anatomically, the left hilum typically sits slightly higher than the right due to the position of the aortic arch. This asymmetry is normal and should not be mistaken for pathological enlargement. A lymph node at the hilum is generally considered enlarged when its short-axis diameter exceeds 10 mm on computed tomography (CT) imaging, although clinical context always informs interpretation.
Hilar Lymph Node Enlargement: Causes and Associated Conditions
Hilar lymph node enlargement, medically termed hilar lymphadenopathy, refers to an increase in the size or number of visible lymph nodes at the lung hilum, most commonly identified on chest imaging. The condition is not a disease in itself but rather a radiological sign that signals an underlying process requiring further evaluation. Its causes span a wide spectrum, from entirely benign and self-limiting infections to serious malignancies.
Infectious diseases are among the most frequent triggers. Pulmonary tuberculosis (TB), caused by Mycobacterium tuberculosis, is a leading cause globally; the World Health Organization (WHO) estimated 10.6 million new TB cases worldwide in 2022, and hilar node involvement is a recognized feature of primary pulmonary infection. Fungal infections such as histoplasmosis and coccidioidomycosis, both endemic to specific geographic regions, can also produce substantial hilar node swelling. Viral infections, including Epstein-Barr virus and certain adenoviruses, occasionally cause transient enlargement as well.
Beyond infection, the following conditions are established causes of hilar lymphadenopathy:
- Sarcoidosis — a systemic granulomatous disease that accounts for a significant proportion of bilateral hilar adenopathy cases in adults aged 20–40.
- Lymphoma — both Hodgkin and non-Hodgkin subtypes frequently involve mediastinal and hilar nodes.
- Lung cancer — primary bronchogenic carcinoma, particularly small-cell and non-small-cell types, may spread to hilar nodes at an early stage.
- Metastatic cancer — malignancies originating in the breast, kidney, colon, or thyroid can metastasize to hilar stations.
- Silicosis and pneumoconiosis — occupational lung diseases caused by prolonged inhalation of silica or coal dust.
Less commonly, autoimmune conditions such as systemic lupus erythematosus and drug reactions have been documented as contributing factors. Identifying the specific cause is essential, as management differs substantially between, for example, a self-resolving viral illness and a lymphoma requiring systemic therapy.
Recognizing Hilar Lymphadenopathy: Symptoms, Chest X-Ray Findings, and Diagnosis
Hilar lymphadenopathy (HLA) often produces no symptoms on its own and is discovered incidentally during routine chest imaging performed for another reason. When symptoms do appear, they tend to reflect either the mass effect of enlarged nodes on adjacent structures or the systemic nature of the underlying disease. Common presentations include a persistent dry cough, shortness of breath, chest tightness, and — particularly in infectious or inflammatory conditions — fever, night sweats, and unintentional weight loss. Severe enlargement may compress the bronchi, causing wheezing or recurrent respiratory infections.
The enlarged hilar lymph nodes on a chest X-ray typically appear as lobulated, dense opacities projecting outward from the normal hilar shadow, giving the hila a “potato-shaped” or “bulky” appearance. Radiologists describe the degree of enlargement as mild, moderate, or marked and note whether one side or both sides are affected. Bilateral hilar lymphadenopathy, meaning simultaneous enlargement on both the left and right sides, is a particularly significant finding: when paired with normal lung fields and the absence of mediastinal widening in a young adult, it strongly suggests sarcoidosis, which accounts for up to 90% of such radiological patterns in that demographic according to published clinical reviews.
When a chest X-ray raises concern, CT of the chest with contrast is the next standard step. CT provides precise node measurements, characterizes internal density (calcification suggests prior TB or histoplasmosis; necrosis raises concern for active infection or high-grade lymphoma), and maps the extent of disease. Positron emission tomography (PET-CT) is often added when malignancy is suspected, as metabolically active nodes show increased radiotracer uptake. Tissue sampling through bronchoscopy with endobronchial ultrasound-guided biopsy (EBUS), mediastinoscopy, or CT-guided fine-needle aspiration provides the histological confirmation needed to distinguish between infection, granulomatous disease, and cancer. Blood tests, including a complete blood count, lactate dehydrogenase, angiotensin-converting enzyme level, and serology for fungal or mycobacterial pathogens, guide the differential diagnosis alongside imaging.
| Diagnostic Tool | Primary Use | Key Information Obtained |
|---|---|---|
| Chest X-ray | Initial screening | Node visibility, symmetry, associated lung changes |
| CT Chest (contrast) | Detailed characterization | Node size, density, calcification, necrosis |
| PET-CT | Malignancy evaluation | Metabolic activity, disease extent |
| EBUS-guided biopsy | Tissue diagnosis | Histology: granuloma, lymphoma, carcinoma |
| Blood tests / serology | Systemic workup | ACE level, CBC, fungal/mycobacterial titers |
Treatment Options and the Cancer Connection in Hilar Lymph Nodes
Treatment of hilar lymph node swelling is directed entirely at the underlying cause rather than at the nodes themselves. In infectious etiologies, appropriate antimicrobial therapy resolves the adenopathy as the pathogen is cleared — pulmonary TB, for instance, is treated with a standard four-drug regimen over six months as recommended by the WHO, and hilar nodes typically decrease in size as therapy progresses. Fungal infections may require antifungal agents such as itraconazole or amphotericin B, depending on severity and immune status.
Sarcoidosis, which is a common non-infectious cause, often resolves spontaneously in mild cases without intervention. When organ function is threatened or symptoms are persistent, oral corticosteroids such as prednisone are the first-line treatment. Disease-modifying agents including methotrexate or azathioprine are used for steroid-sparing maintenance in chronic or relapsing disease. Regular pulmonary function testing and imaging guide the duration of therapy.
The hilar lymph nodes cancer connection is clinically significant and warrants careful attention. Lung cancer is the leading cause of cancer-related death worldwide, with approximately 2.21 million new cases recorded by the WHO in 2020. Involvement of ipsilateral hilar nodes — nodes on the same side as the primary tumor — is classified as N1 disease in the lung cancer staging system, while spread to contralateral hilar or mediastinal nodes constitutes N2 or N3 disease and typically places patients in a surgically unresectable category. In these cases, treatment shifts toward systemic chemotherapy, targeted therapy (for tumors with actionable mutations such as EGFR, ALK, or ROS1 alterations), immunotherapy with checkpoint inhibitors, or concurrent chemoradiation.
For lymphoma involving hilar nodes, management depends on subtype and stage. Hodgkin lymphoma, which frequently presents with mediastinal and hilar involvement in young adults, is highly treatable with combination chemotherapy regimens such as ABVD, achieving long-term remission in the majority of patients when diagnosed at an early stage. Non-Hodgkin lymphoma treatment is more heterogeneous, requiring immunotherapy combinations tailored to the specific histological subtype. Metastatic carcinomas reaching the hilum from distant primary sites are generally managed with systemic therapy guided by the primary tumor’s molecular profile, and local radiation may be added to relieve compressive symptoms. In all cases, a multidisciplinary team including pulmonology, oncology, thoracic surgery, and radiology collaborates to determine the optimal treatment pathway.
Frequently Asked Questions
Can hilar lymph node enlargement resolve on its own?
Yes, in many cases hilar lymphadenopathy resolves without treatment, particularly when caused by a self-limiting viral infection or early-stage sarcoidosis. However, spontaneous resolution should always be confirmed with follow-up imaging, as persistent or progressive enlargement requires further investigation to exclude malignancy or chronic infection. A physician should monitor any identified enlargement until it fully resolves or a definitive diagnosis is established.
Is bilateral hilar lymphadenopathy always serious?
Not always. Bilateral hilar lymphadenopathy in a young adult with no other symptoms and normal lung fields on imaging is most commonly caused by sarcoidosis, which has a favorable prognosis in many patients. However, it can also indicate lymphoma or other systemic diseases. A thorough workup including blood tests and, when needed, tissue biopsy is necessary to confirm the cause and determine whether treatment is required.
How are hilar lymph nodes different from mediastinal lymph nodes?
Hilar lymph nodes are located specifically at the hilum of each lung, the entry point for bronchi and blood vessels. Mediastinal lymph nodes are distributed throughout the central chest cavity between the lungs. The two groups are anatomically adjacent and communicate through lymphatic channels, which is why disease such as lung cancer or lymphoma can affect both simultaneously. Distinguishing their involvement matters for staging and selecting the appropriate treatment approach.
